Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Research Report 2026(Status and Outlook)
AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market size was estimated at USD 846.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 5.40% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market.
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
BioMarin Pharmaceutical
Sangamo Therapeutics
Amicus Therapeutics
Roche
Pfizer
NightstaRx
MeiraGTx
Sarepta Therapeutics
Neurocrine Biosciences
Voyager Therapeutics
Asklepios Biopharmaceutical
Market Segmentation (by Type)
Single-stranded AAV (ssAAV)
Self-complementary AAV (scAAV)
Market Segmentation (by Application)
Hemophilia
Ophthalmology
Lysosomal Storage Disorders
Neurological Disorders
Others
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
Overview of the regional outlook of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market size was estimated at USD 846.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 5.40% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market.
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
BioMarin Pharmaceutical
Sangamo Therapeutics
Amicus Therapeutics
Roche
Pfizer
NightstaRx
MeiraGTx
Sarepta Therapeutics
Neurocrine Biosciences
Voyager Therapeutics
Asklepios Biopharmaceutical
Market Segmentation (by Type)
Single-stranded AAV (ssAAV)
Self-complementary AAV (scAAV)
Market Segmentation (by Application)
Hemophilia
Ophthalmology
Lysosomal Storage Disorders
Neurological Disorders
Others
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
Overview of the regional outlook of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
1.2 Key Market Segments
1.2.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Type
1.2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Life Cycle
3.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Manufacturers (2020-2025)
3.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Manufacturers (2020-2025)
3.5 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Competitive Situation and Trends
3.8.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Rate
3.8.2 Global 5 and 10 Largest Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY INDUSTRY CHAIN ANALYSIS
4.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
5.7 ESG Ratings of Leading Companies
6 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Type (2020-2025)
6.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2020-2025)
6.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Price by Type (2020-2025)
7 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Sales by Application (2020-2025)
7.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) by Application (2020-2025)
7.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Growth Rate by Application (2020-2025)
8 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET SALES BY REGION
8.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region
8.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region
8.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region
8.2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region
8.3 North America
8.3.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country
8.3.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country
8.4.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.5.2 Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country
8.6.2 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.7.2 Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET PRODUCTION BY REGION
9.1 Global Production of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Region(2020-2025)
9.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Region (2020-2025)
9.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production
9.4.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production Growth Rate (2020-2025)
9.4.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production
9.5.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production Growth Rate (2020-2025)
9.5.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (2020-2025)
9.6.1 Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production Growth Rate (2020-2025)
9.6.2 Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (2020-2025)
9.7.1 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production Growth Rate (2020-2025)
9.7.2 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 BioMarin Pharmaceutical
10.1.1 BioMarin Pharmaceutical Basic Information
10.1.2 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.1.4 BioMarin Pharmaceutical Business Overview
10.1.5 BioMarin Pharmaceutical SWOT Analysis
10.1.6 BioMarin Pharmaceutical Recent Developments
10.2 Sangamo Therapeutics
10.2.1 Sangamo Therapeutics Basic Information
10.2.2 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.2.4 Sangamo Therapeutics Business Overview
10.2.5 Sangamo Therapeutics SWOT Analysis
10.2.6 Sangamo Therapeutics Recent Developments
10.3 Amicus Therapeutics
10.3.1 Amicus Therapeutics Basic Information
10.3.2 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.3.4 Amicus Therapeutics Business Overview
10.3.5 Amicus Therapeutics SWOT Analysis
10.3.6 Amicus Therapeutics Recent Developments
10.4 Roche
10.4.1 Roche Basic Information
10.4.2 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.4.4 Roche Business Overview
10.4.5 Roche Recent Developments
10.5 Pfizer
10.5.1 Pfizer Basic Information
10.5.2 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.5.4 Pfizer Business Overview
10.5.5 Pfizer Recent Developments
10.6 NightstaRx
10.6.1 NightstaRx Basic Information
10.6.2 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.6.4 NightstaRx Business Overview
10.6.5 NightstaRx Recent Developments
10.7 MeiraGTx
10.7.1 MeiraGTx Basic Information
10.7.2 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.7.4 MeiraGTx Business Overview
10.7.5 MeiraGTx Recent Developments
10.8 Sarepta Therapeutics
10.8.1 Sarepta Therapeutics Basic Information
10.8.2 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.8.4 Sarepta Therapeutics Business Overview
10.8.5 Sarepta Therapeutics Recent Developments
10.9 Neurocrine Biosciences
10.9.1 Neurocrine Biosciences Basic Information
10.9.2 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.9.4 Neurocrine Biosciences Business Overview
10.9.5 Neurocrine Biosciences Recent Developments
10.10 Voyager Therapeutics
10.10.1 Voyager Therapeutics Basic Information
10.10.2 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.10.4 Voyager Therapeutics Business Overview
10.10.5 Voyager Therapeutics Recent Developments
10.11 Asklepios Biopharmaceutical
10.11.1 Asklepios Biopharmaceutical Basic Information
10.11.2 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.11.4 Asklepios Biopharmaceutical Business Overview
10.11.5 Asklepios Biopharmaceutical Recent Developments
11 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET FORECAST BY REGION
11.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast
11.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country
11.2.3 Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Region
11.2.4 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type (2026-2035)
12.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type (2026-2035)
12.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Application (2026-2035)
12.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT) Forecast by Application
12.2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
1.2 Key Market Segments
1.2.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Type
1.2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Life Cycle
3.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Manufacturers (2020-2025)
3.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Manufacturers (2020-2025)
3.5 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Competitive Situation and Trends
3.8.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Rate
3.8.2 Global 5 and 10 Largest Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY INDUSTRY CHAIN ANALYSIS
4.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
5.7 ESG Ratings of Leading Companies
6 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Type (2020-2025)
6.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2020-2025)
6.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Price by Type (2020-2025)
7 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Sales by Application (2020-2025)
7.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) by Application (2020-2025)
7.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Growth Rate by Application (2020-2025)
8 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET SALES BY REGION
8.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region
8.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region
8.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region
8.2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region
8.3 North America
8.3.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country
8.3.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country
8.4.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.5.2 Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country
8.6.2 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.7.2 Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET PRODUCTION BY REGION
9.1 Global Production of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Region(2020-2025)
9.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Region (2020-2025)
9.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production
9.4.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production Growth Rate (2020-2025)
9.4.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production
9.5.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production Growth Rate (2020-2025)
9.5.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (2020-2025)
9.6.1 Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production Growth Rate (2020-2025)
9.6.2 Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (2020-2025)
9.7.1 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production Growth Rate (2020-2025)
9.7.2 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 BioMarin Pharmaceutical
10.1.1 BioMarin Pharmaceutical Basic Information
10.1.2 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.1.4 BioMarin Pharmaceutical Business Overview
10.1.5 BioMarin Pharmaceutical SWOT Analysis
10.1.6 BioMarin Pharmaceutical Recent Developments
10.2 Sangamo Therapeutics
10.2.1 Sangamo Therapeutics Basic Information
10.2.2 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.2.4 Sangamo Therapeutics Business Overview
10.2.5 Sangamo Therapeutics SWOT Analysis
10.2.6 Sangamo Therapeutics Recent Developments
10.3 Amicus Therapeutics
10.3.1 Amicus Therapeutics Basic Information
10.3.2 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.3.4 Amicus Therapeutics Business Overview
10.3.5 Amicus Therapeutics SWOT Analysis
10.3.6 Amicus Therapeutics Recent Developments
10.4 Roche
10.4.1 Roche Basic Information
10.4.2 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.4.4 Roche Business Overview
10.4.5 Roche Recent Developments
10.5 Pfizer
10.5.1 Pfizer Basic Information
10.5.2 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.5.4 Pfizer Business Overview
10.5.5 Pfizer Recent Developments
10.6 NightstaRx
10.6.1 NightstaRx Basic Information
10.6.2 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.6.4 NightstaRx Business Overview
10.6.5 NightstaRx Recent Developments
10.7 MeiraGTx
10.7.1 MeiraGTx Basic Information
10.7.2 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.7.4 MeiraGTx Business Overview
10.7.5 MeiraGTx Recent Developments
10.8 Sarepta Therapeutics
10.8.1 Sarepta Therapeutics Basic Information
10.8.2 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.8.4 Sarepta Therapeutics Business Overview
10.8.5 Sarepta Therapeutics Recent Developments
10.9 Neurocrine Biosciences
10.9.1 Neurocrine Biosciences Basic Information
10.9.2 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.9.4 Neurocrine Biosciences Business Overview
10.9.5 Neurocrine Biosciences Recent Developments
10.10 Voyager Therapeutics
10.10.1 Voyager Therapeutics Basic Information
10.10.2 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.10.4 Voyager Therapeutics Business Overview
10.10.5 Voyager Therapeutics Recent Developments
10.11 Asklepios Biopharmaceutical
10.11.1 Asklepios Biopharmaceutical Basic Information
10.11.2 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
10.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
10.11.4 Asklepios Biopharmaceutical Business Overview
10.11.5 Asklepios Biopharmaceutical Recent Developments
11 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET FORECAST BY REGION
11.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast
11.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country
11.2.3 Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Region
11.2.4 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type (2026-2035)
12.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type (2026-2035)
12.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Application (2026-2035)
12.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT) Forecast by Application
12.2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (M USD)
Table 4. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
Table 5. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Comparison by Region (M USD)
Table 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy as of 2025)
Table 11. Global Market Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Type (K MT)
Table 27. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (M USD)
Table 28. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT) by Type (2020-2025)
Table 29. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Type (2020-2025)
Table 30. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) by Type (2020-2025)
Table 31. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2020-2025)
Table 32. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Price (USD/KG) by Type (2020-2025)
Table 33. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT) by Application
Table 34. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
Table 35. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Application (2020-2025) & (K MT)
Table 36. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Application (2020-2025)
Table 37. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2020-2025) & (M USD)
Table 38. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2020-2025)
Table 39. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Growth Rate by Application (2020-2025)
Table 40. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region (2020-2025) & (K MT)
Table 41. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region (2020-2025)
Table 42. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2020-2025) & (M USD)
Table 43. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2020-2025)
Table 44. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country (2020-2025) & (K MT)
Table 45. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country (2020-2025) & (K MT)
Table 47. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2020-2025) & (M USD)
Table 50. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country (2020-2025) & (K MT)
Table 51. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2020-2025) & (M USD)
Table 54. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K MT) by Region(2020-2025)
Table 55. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Region (2020-2025)
Table 57. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. BioMarin Pharmaceutical Basic Information
Table 63. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 64. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. BioMarin Pharmaceutical Business Overview
Table 66. BioMarin Pharmaceutical SWOT Analysis
Table 67. BioMarin Pharmaceutical Recent Developments
Table 68. Sangamo Therapeutics Basic Information
Table 69. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 70. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Sangamo Therapeutics Business Overview
Table 72. Sangamo Therapeutics SWOT Analysis
Table 73. Sangamo Therapeutics Recent Developments
Table 74. Amicus Therapeutics Basic Information
Table 75. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 76. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Amicus Therapeutics Business Overview
Table 78. Amicus Therapeutics SWOT Analysis
Table 79. Amicus Therapeutics Recent Developments
Table 80. Roche Basic Information
Table 81. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 82. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Roche Business Overview
Table 84. Roche Recent Developments
Table 85. Pfizer Basic Information
Table 86. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 87. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. Pfizer Business Overview
Table 89. Pfizer Recent Developments
Table 90. NightstaRx Basic Information
Table 91. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 92. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. NightstaRx Business Overview
Table 94. NightstaRx Recent Developments
Table 95. MeiraGTx Basic Information
Table 96. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 97. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. MeiraGTx Business Overview
Table 99. MeiraGTx Recent Developments
Table 100. Sarepta Therapeutics Basic Information
Table 101. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 102. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. Sarepta Therapeutics Business Overview
Table 104. Sarepta Therapeutics Recent Developments
Table 105. Neurocrine Biosciences Basic Information
Table 106. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 107. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. Neurocrine Biosciences Business Overview
Table 109. Neurocrine Biosciences Recent Developments
Table 110. Voyager Therapeutics Basic Information
Table 111. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 112. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. Voyager Therapeutics Business Overview
Table 114. Voyager Therapeutics Recent Developments
Table 115. Asklepios Biopharmaceutical Basic Information
Table 116. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 117. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. Asklepios Biopharmaceutical Business Overview
Table 119. Asklepios Biopharmaceutical Recent Developments
Table 120. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Region (2026-2035) & (K MT)
Table 121. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Region (2026-2035) & (M USD)
Table 122. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Country (2026-2035) & (K MT)
Table 123. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country (2026-2035) & (M USD)
Table 124. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Country (2026-2035) & (K MT)
Table 125. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country (2026-2035) & (M USD)
Table 126. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Region (2026-2035) & (K MT)
Table 127. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Region (2026-2035) & (M USD)
Table 128. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Country (2026-2035) & (K MT)
Table 129. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country (2026-2035) & (M USD)
Table 130. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Country (2026-2035) & (Units)
Table 131. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country (2026-2035) & (M USD)
Table 132. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Type (2026-2035) & (K MT)
Table 133. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Type (2026-2035) & (M USD)
Table 134. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Price Forecast by Type (2026-2035) & (USD/KG)
Table 135. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT) Forecast by Application (2026-2035)
Table 136. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (M USD)
Table 4. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
Table 5. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Comparison by Region (M USD)
Table 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy as of 2025)
Table 11. Global Market Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Type (K MT)
Table 27. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (M USD)
Table 28. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT) by Type (2020-2025)
Table 29. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Type (2020-2025)
Table 30. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) by Type (2020-2025)
Table 31. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type (2020-2025)
Table 32. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Price (USD/KG) by Type (2020-2025)
Table 33. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT) by Application
Table 34. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
Table 35. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Application (2020-2025) & (K MT)
Table 36. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Application (2020-2025)
Table 37. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2020-2025) & (M USD)
Table 38. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2020-2025)
Table 39. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Growth Rate by Application (2020-2025)
Table 40. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region (2020-2025) & (K MT)
Table 41. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region (2020-2025)
Table 42. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2020-2025) & (M USD)
Table 43. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2020-2025)
Table 44. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country (2020-2025) & (K MT)
Table 45. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country (2020-2025) & (K MT)
Table 47. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2020-2025) & (M USD)
Table 50. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country (2020-2025) & (K MT)
Table 51. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2020-2025) & (M USD)
Table 54. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K MT) by Region(2020-2025)
Table 55. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Region (2020-2025)
Table 57. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. BioMarin Pharmaceutical Basic Information
Table 63. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 64. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. BioMarin Pharmaceutical Business Overview
Table 66. BioMarin Pharmaceutical SWOT Analysis
Table 67. BioMarin Pharmaceutical Recent Developments
Table 68. Sangamo Therapeutics Basic Information
Table 69. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 70. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Sangamo Therapeutics Business Overview
Table 72. Sangamo Therapeutics SWOT Analysis
Table 73. Sangamo Therapeutics Recent Developments
Table 74. Amicus Therapeutics Basic Information
Table 75. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 76. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Amicus Therapeutics Business Overview
Table 78. Amicus Therapeutics SWOT Analysis
Table 79. Amicus Therapeutics Recent Developments
Table 80. Roche Basic Information
Table 81. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 82. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Roche Business Overview
Table 84. Roche Recent Developments
Table 85. Pfizer Basic Information
Table 86. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 87. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. Pfizer Business Overview
Table 89. Pfizer Recent Developments
Table 90. NightstaRx Basic Information
Table 91. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 92. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. NightstaRx Business Overview
Table 94. NightstaRx Recent Developments
Table 95. MeiraGTx Basic Information
Table 96. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 97. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. MeiraGTx Business Overview
Table 99. MeiraGTx Recent Developments
Table 100. Sarepta Therapeutics Basic Information
Table 101. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 102. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. Sarepta Therapeutics Business Overview
Table 104. Sarepta Therapeutics Recent Developments
Table 105. Neurocrine Biosciences Basic Information
Table 106. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 107. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. Neurocrine Biosciences Business Overview
Table 109. Neurocrine Biosciences Recent Developments
Table 110. Voyager Therapeutics Basic Information
Table 111. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 112. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. Voyager Therapeutics Business Overview
Table 114. Voyager Therapeutics Recent Developments
Table 115. Asklepios Biopharmaceutical Basic Information
Table 116. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
Table 117. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. Asklepios Biopharmaceutical Business Overview
Table 119. Asklepios Biopharmaceutical Recent Developments
Table 120. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Region (2026-2035) & (K MT)
Table 121. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Region (2026-2035) & (M USD)
Table 122. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Country (2026-2035) & (K MT)
Table 123. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country (2026-2035) & (M USD)
Table 124. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Country (2026-2035) & (K MT)
Table 125. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country (2026-2035) & (M USD)
Table 126. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Region (2026-2035) & (K MT)
Table 127. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Region (2026-2035) & (M USD)
Table 128. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Country (2026-2035) & (K MT)
Table 129. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country (2026-2035) & (M USD)
Table 130. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Country (2026-2035) & (Units)
Table 131. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country (2026-2035) & (M USD)
Table 132. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Type (2026-2035) & (K MT)
Table 133. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Type (2026-2035) & (M USD)
Table 134. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Price Forecast by Type (2026-2035) & (USD/KG)
Table 135. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT) Forecast by Application (2026-2035)
Table 136. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD), 2025-2035
Figure 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) (2020-2035)
Figure 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Life Cycle
Figure 13. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Share by Manufacturers in 2025
Figure 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Manufacturers in 2025
Figure 15. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2025
Figure 18. Industry Chain Map of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
Figure 19. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market PEST Analysis
Figure 20. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type
Figure 27. Sales Market Share of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type (2020-2025)
Figure 28. Sales Market Share of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type in 2025
Figure 29. Market Share of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type (2020-2025)
Figure 30. Market Share of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application
Figure 33. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Application (2020-2025)
Figure 34. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Application in 2025
Figure 35. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2020-2025)
Figure 36. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application in 2025
Figure 37. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Growth Rate by Application (2020-2025)
Figure 38. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region (2020-2025)
Figure 39. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2020-2025)
Figure 40. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Country in 2024
Figure 43. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country in 2024
Figure 45. U.S. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Country in 2024
Figure 53. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country in 2024
Figure 55. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region in 2024
Figure 67. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region in 2024
Figure 68. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (K MT)
Figure 79. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Country in 2024
Figure 80. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (M USD)
Figure 81. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country in 2024
Figure 82. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region in 2024
Figure 92. Saudi Arabia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production Market Share by Region (2020-2025)
Figure 103. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K MT) Growth Rate (2020-2025)
Figure 106. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share Forecast by Type (2026-2035)
Figure 111. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Application (2026-2035)
Figure 112. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share Forecast by Application (2026-2035)
Figure 1. Product Picture of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD), 2025-2035
Figure 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) (2020-2035)
Figure 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Life Cycle
Figure 13. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Share by Manufacturers in 2025
Figure 14. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Share by Manufacturers in 2025
Figure 15. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2025
Figure 18. Industry Chain Map of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
Figure 19. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market PEST Analysis
Figure 20. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Type
Figure 27. Sales Market Share of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type (2020-2025)
Figure 28. Sales Market Share of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type in 2025
Figure 29. Market Share of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type (2020-2025)
Figure 30. Market Share of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application
Figure 33. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Application (2020-2025)
Figure 34. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Application in 2025
Figure 35. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application (2020-2025)
Figure 36. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application in 2025
Figure 37. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Growth Rate by Application (2020-2025)
Figure 38. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region (2020-2025)
Figure 39. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2020-2025)
Figure 40. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Country in 2024
Figure 43. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country in 2024
Figure 45. U.S. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Country in 2024
Figure 53. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country in 2024
Figure 55. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region in 2024
Figure 67. Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region in 2024
Figure 68. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (K MT)
Figure 79. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Country in 2024
Figure 80. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (M USD)
Figure 81. South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country in 2024
Figure 82. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region in 2024
Figure 92. Saudi Arabia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production Market Share by Region (2020-2025)
Figure 103. North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K MT) Growth Rate (2020-2025)
Figure 106. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share Forecast by Type (2026-2035)
Figure 111. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Forecast by Application (2026-2035)
Figure 112. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share Forecast by Application (2026-2035)
